35 completed, 7 unknown, 4 terminated, 3 withdrawn. 17 Phase 4, 12 Phase 3, 9 Phase 1, 7 Phase 2, 6 Not applicable.
Follow Dapsone: new trials by email Literature Review of Dapsone trials Research Report on Dapsone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Triple-Blind, Vehicle-Controlled Trial of Topical Dapsone Gel 7.5% in Patients With Acne Vulgaris Dapsone 7.5% gel, Vehicle gel - Acne Vulgaris | Phase 4 | Completed | Oya Helin Dundar | 100 | 2025-06-17 | 2026-05-22 |
| Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients Dapsone - Leprosy, Mycobacterium Leprae Infection | Not applicable | Recruiting | South Valley University | 50 | 2024-12-20 | 2025-02-11 |
| Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid Prednisolone, Dapsone, Methotrexate - Bullous Pemphigoid | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 62 | 2023-08-01 | 2025-08-14 |
| Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 Dapsone 85 mg PO BID, Placebo 85 mg PO BID - COVID-19 | Phase 3 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 3000 | 2021-11-22 | 2022-02-24 |
| Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment Dapsone 100 MG - SARS-CoV-2, Hypoxia | Early Phase 1 | Unknown | Hunt Regional Medical Center | 100 | 2020-10-18 | 2021-06-09 |
| Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP - Benign Mucous Membrane Pemphigoid | Phase 2 / Phase 3 | Unknown | Tanta University | 10 | 2020-09-30 | 2021-02-09 |
| Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) - Acne Vulgaris | Phase 3 | Completed | Torrent Pharmaceuticals Limited | 1150 | 2019-07-11 | 2020-04-02 |
| Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color Aczone Gel - Acne Vulgaris | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 20 | 2019-04-09 | 2022-07-27 |
| A Randomized Multicenter Study for Isolated Skin Vasculitis Colchicine, Dapsone, Azathioprine - Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa | Phase 2 | Recruiting | University of Pennsylvania | 90 | 2017-01-01 | 2026-08-20 |
| Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris dapsone gel - Acne Vulgaris | Phase 4 | Completed | Almirall, S.A. | 100 | 2016-10-31 | 2020-03-03 |
| Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Dapsone 7.5 % gel - Acne | Phase 4 | Completed | Derm Research, PLLC | 20 | 2016-10-01 | 2019-04-03 |
| Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris DPSG 7.5%, Aczone, Placebo - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1125 | 2016-08-08 | 2017-05-04 |
| Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan) - Acne Vulgaris | Phase 3 | Completed | Seegpharm S.A. | 2361 | 2016-02-01 | 2016-12-20 |
| Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Dapsone (Disulone®), Prednisone (Cortancyl®) alone followed by monitoring and "standard of care", Prednisone (Cortancyl®) - Adult Immune Thrombocytopenia (ITP), Dapsone | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 216 | 2015-12-01 | 2017-07-26 |
| Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Dapsone, HLA-B*1301 - Allergic Cutaneous Vasculitis, Urticaria | Phase 4 | Unknown | Shandong Provincial Institute of Dermatology and Venereology | 3130 | 2015-07-01 | 2017-03-03 |
| Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris Test., Aczone Gel 5%, Placebo - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1134 | 2014-04-01 | 2017-05-04 |
| A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Dapsone Gel - Acne Vulgaris | Phase 4 | Completed | Allergan | 68 | 2013-12-01 | 2015-08-19 |
| Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Topical Dapsone 5% Gel, Moisturizer, oral antibiotics - Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 11 | 2013-08-01 | 2017-01-13 |
| Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Doxycycline 100mg, Aczone 5% gel - Acne Vulgaris | Phase 4 | Completed | Derm Research, PLLC | 32 | 2013-07-01 | 2015-02-27 |
| An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris Dapsone Formulation A, Dapsone Formulation B, Dapsone Formulation C - Acne Vulgaris | Phase 1 | Withdrawn | Allergan | 2013-03-01 | 2013-02-25 |
Showing 20 of 51. Sign in to see all of them.
Acne Vulgaris (19) · HIV Infections (10) · Pneumonia, Pneumocystis (10) · Acquired Immunodeficiency Syndrome (9) · AIDS-Related Complex (4) · AIDS-Related Opportunistic Infections (4) · Leprosy (4) · Erythema (2) · Exanthema (2) · Methemoglobinemia (2) · Skin Diseases (2) · Anemia (1) · Anemia, Aplastic (1) · Aneurysm (1) · Bacterial Infections (1)
Allergan (9) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Jacobus Pharmaceutical (3) · Derm Research, PLLC (2) · Sun Pharmaceutical Industries, Inc. (2) · All India Institute of Medical Sciences, Bhubaneswar (1) · Almirall, S.A. (1) · Assistance Publique - Hôpitaux de Paris (1) · Bausch Health Americas, Inc. (1) · Chiang Mai University (1) · Cidat, S.A. de C.V. (1) · El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (1) · George Washington University (1) · Hadassah Medical Organization (1) · Hospital Clinic of Barcelona (1)
United States (33) · Tanzania (3) · Belize (2) · Canada (2) · Egypt (2) · Mexico (2) · Brazil (1) · China (1) · France (1) · Germany (1) · India (1) · Israel (1) · Japan (1) · Puerto Rico (1) · Thailand (1)
El-Sadr W (2) · Luskin-Hawk R (2) · Steven Garrett, MS, DDS (2) · Adam J. Esbenshade, MD (1) · Afsoon Roberts, M.D. (1) · Amit Pandya, MD (1) · Ayse Esra Koku Aksu, MD, Prof. (1) · Black JR (1) · Caryn Thompson, MBA (1) · Cathy Truong (1) · Christian Pagnoux, MD, MPH, MSc (1) · Clara Menendez, MD, PhD (1) · Cooper E (1)
PMID 15470330, PMID 17509235, PMID 18209165, PMID 23373662, PMID 28222139, PMID 28704363, PMID 29867930, PMID 32345372, PMID 36853224, PMID 38697216, PMID 39874521, PMID 9310602
5UL1RR024982-02 (1), P30CA068485 (1), U54AR057319 (1)